Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma Journal Article

  


Authors: Genega, E. M.; Hutchinson, B.; Reuter, V. E.; Gaudin, P. B.
Article Title: Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma
Abstract: Morphologic features alone can usually be used to distinguish prostatic adenocarcinoma and urothelial carcinoma of the urinary bladder. Poorly differentiated tumors, however, can occasionally have features of both neoplasms, making determination of site of origin difficult. No study has provided a panel of antibodies to assist in the distinction of these two tumors. For this study, 73 examples of moderately and poorly differentiated prostatic adenocarcinoma and 46 examples of high-grade urothelial carcinoma were obtained from radical resection specimens. Immunohistochemical studies were performed using the following panel of antibodies: cytokeratin (CK) 7, CK 20, 34βE12, Leu M1, carcinoembryonic antigen (CEA)m, CEAp, p53, Leu 7, prostate-specific acid phosphatase (PSAP), prostate-specific antigen (PSA), and B72.3. Mucicarmine was also performed. Intermediate and high-grade prostatic carcinoma were compared and then high-grade prostatic carcinoma was compared with high-grade urothelial carcinoma. PSA and PSAP each stained 94% of prostatic adenocarcinomas, but no urothelial carcinomas. Leu 7 stained 94% of prostate and 17% of urothelial carcinomas. Over half of the urothelial carcinomas showed positivity for 34βE12 (65%), as did two cases of prostatic carcinoma (6%). Eighty-three percent of urothelial carcinomas and 12% of prostatic adenocarcinomas stained with CK 7. Forty-one percent of urothelial carcinomas and 12% of prostatic carcinomas were reactive for CEAm, and p53 stained 33% and 3% of urothelial and prostatic adenocarcinomas, respectively. No significant difference was seen in the expression of CEAp, CK 20, B72.3, Leu M1, or mucicarmine between prostate and urothelial carcinoma. We propose a panel of six antibodies to assist in the distinction of high-grade prostatic adenocarcinoma from high grade urothelial carcinoma: PSA, PSAP, 34βE12, Leu 7, CK 7, and p53. The first three antibodies should be used initially; if results are negative, the remaining antibodies may be employed.
Keywords: immunohistochemistry; controlled study; human tissue; cancer grading; adenocarcinoma; antigen expression; prostate specific antigen; carcinoembryonic antigen; neoplasm proteins; tumor markers, biological; immunoreactivity; urinary bladder neoplasms; prostatic neoplasms; immunoenzyme techniques; urothelium; psa; urothelial carcinoma; immunophenotyping; cytokeratin 20; prostate adenocarcinoma; cytokeratin 7; carcinoma, transitional cell; bladder carcinoma; prostatic adenocarcinoma; humans; human; male; priority journal; article; 34βe12; ck 7; leu 7; psap
Journal Title: Modern Pathology
Volume: 13
Issue: 11
ISSN: 0893-3952
Publisher: Nature Research  
Date Published: 2000-11-01
Start Page: 1186
End Page: 1191
Language: English
PUBMED: 11106075
PROVIDER: scopus
DOI: 10.1038/modpathol.3880220
DOI/URL:

http://www.scopus.com/inward/record.url?eid=2-s2.0-0033711090&partnerID=40&md5=c729821834499edc6e95cc0452e1401c
Notes: Export Date: 18 November 2015 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Elizabeth M Genega
    17 Genega
  2. Paul B Gaudin
    57 Gaudin
  3. Victor Reuter
    1223 Reuter
  4. J Brian Hutchinson
    35 Hutchinson
Related MSK Work